CYP7B1 and Spastic paraparesis: There is no evidence that CDCA treatment can prevent the spastic paraparesis caused by biallelic CYP7B1 mutations, although in induced pluripotent stem cell‐derived neurons from patients, CYP7B1 deficiency leads to impaired neurofilament expression as well as axonal degeneration, which could be rescued with CDCA [68].